FFA
CRSP icon

Farther Finance Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Farther Finance Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$434K Sell
7,956
-995
-11% -$52.4K ﹤0.01% 1655
2026
Q1 		$437K Buy
8,951
+211
+2% +$11.1K ﹤0.01% 1499
2025
Q4 		$458K Buy
8,740
+1,235
+16% +$74K ﹤0.01% 1364
2025
Q3 		$486K Sell
7,505
-588
-7% -$33.8K 0.01% 1081
2025
Q2 		$394K Buy
8,093
+2,467
+44% +$95.5K 0.01% 1029
2025
Q1 		$186K Buy
5,626
+1,792
+47% +$76K ﹤0.01% 1257
2024
Q4 		$151K Buy
3,834
+977
+34% +$46.1K 0.01% 1123
2024
Q3 		$134K Buy
2,857
+195
+7% +$9.89K 0.01% 1174
2024
Q2 		$144K Buy
2,662
+68
+3% +$3.93K 0.01% 983
2024
Q1 		$177K Buy
2,594
+502
+24% +$35.9K 0.01% 728
2023
Q4 		$131K Buy
2,092
+1,892
+946% +$105K 0.01% 702
2023
Q3 		$9.08K Sell
200
-160
-44% -$8.26K ﹤0.01% 1318
2023
Q2 		$20.2K Sell
360
-379
-51% -$21.5K ﹤0.01% 993
2023
Q1 		$33.4K Buy
739
+728
+6,618% +$35.4K 0.01% 732
2022
Q4 		$447 Buy
+11
New +$584 ﹤0.01% 1854

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Farther Finance Advisors's CRSP Position: Q2 2026 in Review

Farther Finance Advisors reduced its CRISPR Therapeutics (CRSP) stake by 11% in Q2 2026, selling an estimated $52.4K and leaving 7,956 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Farther Finance Advisors first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. The position peaked at $486K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Farther Finance Advisors held 7,956 shares of CRISPR Therapeutics worth $434K as of Q2 2026.
  • Farther Finance Advisors sold 995 CRISPR Therapeutics shares in Q2 2026, an estimated $52.4K.
  • CRISPR Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #1655 holding.
  • Farther Finance Advisors first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's CRISPR Therapeutics position peaked at $486K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.